News Quantified

VCYT – veracyte, inc. (US:NASDAQ)

Veracyte (VCYT) Valuation Check After Strong 2025 Earnings And Reaffirmed 2026 Growth Outlook [Yahoo! Finance]

Wisdom Bioscience Establishes Scientific Advisory Board to Advance Oral Cancer Diagnostics and Screening [Yahoo! Finance]

Veracyte (VCYT) had its price target raised by Needham & Company LLC from $44.00 to $48.00. They now have a "buy" rating on the stock.

Veracyte Q4 Earnings Call Highlights [Yahoo! Finance]

Veracyte outlines 10%–13% revenue growth for 2026 while advancing MRD and Prosigna launches [Seeking Alpha]

Live Event: Join our next subscriber-only event: "The Data Driven Investor"

Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com

Click Here To Register For The Live Online Workshop

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

52 Week High	{{GetCompanyStockInfo.Week52HighValue}} {{GetCompanyStockInfo.Week52HighDate}}
52 Week Low	{{GetCompanyStockInfo.Week52LowValue}} {{GetCompanyStockInfo.Week52LowDate}}

Today’s Volatility	{{VolatilityStr}}
20 Day Volatility	{{Volatility20Str}}

Open	{{GetCompanyStockInfo.Open}}
Prior Close	{{GetCompanyStockInfo.PriorCloseValue}} {{GetCompanyStockInfo.PriorCloseDate}}